


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.22%
+2.06%
+105.44%
CABA
Cabaletta Bio Inc.
$2.33
Chart
$2.85 (-18.25%)
$1.6 (+45.63%)
$1.77 (+31.64%)
$3.01 (-22.59%)
CABA has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

CABA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
CABA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CABA Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayWhat is CABA current stock price?
What are CABA stock strengths?
What risks are associated with CABA stock?
When is CABA next earnings report?
What is CABA market cap and volume?
What is CABA's current Stock IQ?
Should I buy CABA stock right now?
Is CABA a Strong Buy right now?
What does a 'Strong Buy' rating mean for CABA?
What does a 'Strong Sell' rating mean for CABA?
What factors influence CABA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.22%
+2.06%
+105.44%
CABA
Cabaletta Bio Inc.
Current Price
$2.33

Chart
$2.85 (-18.25%)
$1.6 (+45.63%)
$1.77 (+31.64%)
$3.01 (-22.59%)
CABA Analysts Opinion
CABA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
![]()
CABA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CABA Street Sentiment is extremely bullish and have positive views on the near-term outlook
CABA has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Price under $5

High volatilty

Average key support and resistance price levels.
CABA Latest Analysis
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update. Rese-cel data presented at multiple medical meetings demonstrated potentially transformative drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use
Mon Nov 10, 2025
Cabaletta Bio Reports Positive Rese-cel Data Across Myositis SSc and SLE Trials. Cabaletta Bio Inc. (NASDAQ:CABA) is one of the best stocks under $3 to invest in. On October 27 Cabaletta Bio announced positive clinical data and development updates for its investigational targeted cell therapy rese-cel (resecabtagene autoleucel formerly known as CABA-201) across its RESET-Myositis RESET-SSc and RESET-SLE trials. As of October 24 the overall RESET program had [….]
Fri Oct 31, 2025
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025. – All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint demonstrating major TIS responses with no immunomodulators –– Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TI
Mon Oct 27, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CABA Stock trends
CABA Stock performance
CABA Stock analysis
CABA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.